{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:54:42Z","timestamp":1778698482912,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ahj.2025.02.014","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T06:46:57Z","timestamp":1740206817000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial"],"prefix":"10.1016","volume":"285","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-9361","authenticated-orcid":false,"given":"Isabela Bispo Santos da Silva","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo H.M.","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano F.","family":"Drager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Gabriel Melo","family":"de Barros e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Dantas Tavares de","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Araruna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno C.","family":"Bacchiega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanderson","family":"Cauduro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edilson","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Loureiro","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odilson","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas P.","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian M.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariane Nascimento","family":"Luz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cecilia Alcantara","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Rodrigues","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Saretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilia Harumi H.S.","family":"Rehder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludhmila Abrahao","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Lopes-Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Kalil Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ahj.2025.02.014_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ahj.2025.02.014_bib0002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends\u2013An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.ahj.2025.02.014_bib0003","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ahj.2025.02.014_bib0004","article-title":"Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer","volume":"2","author":"Zaheed","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ahj.2025.02.014_bib0005","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.ahj.2025.02.014_bib0006","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2025.02.014_bib0007","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaccao.2023.08.003","article-title":"Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Salloum","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"21","key":"10.1016\/j.ahj.2025.02.014_bib0008","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"Mann","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2025.02.014_bib0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.ahj.2025.02.014_bib0010","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart","volume":"44","author":"de Nigris","year":"2008","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"21","key":"10.1016\/j.ahj.2025.02.014_bib0011","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2025.02.014_bib0012","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"issue":"20","key":"10.1016\/j.ahj.2025.02.014_bib0013","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2025.02.014_bib0014","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2025.02.014_bib0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2025.02.014_bib0016","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res: BCR"},{"issue":"11","key":"10.1016\/j.ahj.2025.02.014_bib0017","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"10.1016\/j.ahj.2025.02.014_bib0018","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ahj.2025.02.014_bib0019","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2025.02.014_bib0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JOP.18.00207","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update summary","volume":"14","author":"Denduluri","year":"2018","journal-title":"J Oncol Pract"},{"issue":"3","key":"10.1016\/j.ahj.2025.02.014_bib0021","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"issue":"6","key":"10.1016\/j.ahj.2025.02.014_bib0022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.ahj.2025.02.014_bib0023","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.15603","article-title":"Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines","volume":"183","author":"Baech","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ahj.2025.02.014_bib0024","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2025.02.014_bib0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2025.02.014_bib0026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ahj.2025.02.014_bib0027","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ahj.2025.02.014_bib0028","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"1","key":"10.1016\/j.ahj.2025.02.014_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.ahj.2025.02.014_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"17","key":"10.1016\/j.ahj.2025.02.014_bib0031","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.ahj.2025.02.014_bib0032","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2025.02.014_bib0033","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0022-2828(90)91011-U","article-title":"Oxygen radical-mediated injury of myocytes-protection by propranolol","volume":"22","author":"Mak","year":"1990","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2025.02.014_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.15.1","article-title":"Protective effects of adrenoceptor-blocking agents on myocardial injury induced by epinephrine in mice","volume":"15","author":"Kubota","year":"1990","journal-title":"J Toxicol Sci"},{"issue":"4","key":"10.1016\/j.ahj.2025.02.014_bib0035","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3892\/etm.2014.1863","article-title":"Cardioprotective effect of carvedilol: inhibition of apoptosis in H9c2 cardiomyocytes via the TLR4\/NF-kappaB pathway following ischemia\/reperfusion injury","volume":"8","author":"Zhao","year":"2014","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.ahj.2025.02.014_bib0036","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCULATIONAHA.116.022304","article-title":"Leukocyte-expressed beta2-adrenergic receptors are essential for survival after acute myocardial injury","volume":"134","author":"Grisanti","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2025.02.014_bib0037","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2025.02.014_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.968534","article-title":"Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis","volume":"9","author":"He","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"27","key":"10.1016\/j.ahj.2025.02.014_bib0039","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2025.02.014_bib0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/187152906779010746","article-title":"Carvedilol: just another Beta-blocker or a powerful cardioprotector?","volume":"6","author":"Carreira","year":"2006","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"6","key":"10.1016\/j.ahj.2025.02.014_bib0041","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ahj.2025.02.014_bib0042","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahj.2025.02.014_bib0043","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s12032-009-9396-4","article-title":"Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era","volume":"27","author":"Beal","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.ahj.2025.02.014_bib0044","unstructured":"Clinicaltrials. Available at internet: https:\/\/www.clinicaltrials.gov\/ct2\/home. Accessed on 12-Jun-2024."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:59:24Z","timestamp":1762077564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":44,"alternative-id":["S0002870325000456"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.02.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}